PUMA Made 7 Out of 10 Products from Better Materials In 2022
24.5.2023 12:28:00 EEST | Business Wire | Press release
Sports company PUMA made 7 out of 10 products from better materials in 2022, according to the company’s Sustainability Report 2022, as it further scaled up the use of recycled materials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005783/en/
Sports company PUMA has made 7 out of 10 products from better materials in 2022, according to the company’s Sustainability Report 2022, as it further scaled up the use of recycled materials. (Photo: Business Wire)
Better materials, such as cotton and viscose from certified sources or recycled polyester, have a smaller environmental footprint in terms of CO2 emissions and allow PUMA to improve its environmental impact across its product range. Since 2017, we have been able to reduce PUMA’s CO2 emissions from materials by 32%. Overall CO2 emissions could be reduced by 7%*, despite a significant growth in sales..
“Our Forever Better strategy aims to make PUMA better across the entire value chain, whether it comes to materials, carbon emissions, circularity or human rights,” said Anne-Laure Descours, Chief Sourcing Officer at PUMA. “We know there is still a lot of work to be done, but we are encouraged by the progress we made last year.”
While PUMA, which is on track to reach its goal of making 9 out of 10 products with better materials by 2025, continued to power 100%* of its offices, stores and warehouses with renewable energy in 2022, its suppliers also increased the use of renewable energy in the supply chain, where most of PUMA’s carbon emissions originate.
PUMA’s core suppliers, which represent approximately 80% of PUMA’s production volume, more than doubled their consumption of renewable energy in just one year, from 0.2% in 2017 to 11% in 2022. This was achieved through the installation of large-scale solar power systems at selected suppliers and the purchase of renewable energy certificates. By 2025, PUMA aims to more than double this figure once again and get its core suppliers to source a quarter of their energy needs from renewable sources.
More than 50% of the polyester used in PUMA’s apparel and accessories came from recycled materials and the company also started to scale up the use of recycled cotton.
At the same time, PUMA made progress with its Forever Better experiments RE:SUEDE, which tests for a biodegradable sneaker, and RE:FIBRE, which aims to scale up more advanced polyester recycling technologies. Both projects continue in 2023.
To ensure that the rights of the more than half a million workers in PUMA’s supply chain were upheld, the company collected audit reports from 510 factories producing finished products and materials in 2022.
PUMA’s sustainability report is available at https://annual-report.puma.com.. As a result of the feedback PUMA received during its first “Conference of the People” in London in 2022 and to reach out to young audiences, parts of the sustainability report will also be made available as a podcast on Spotify, launching June 1, 2023.
*Including renewable energy attribute certificates
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005783/en/
Contact information
Kerstin Neuber - Corporate Communications - PUMA SE - Kerstin.neuber@puma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom